DSY Dassault Systemes SA

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey 

Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care

New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the , building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge will advance studies, amplifying the development of therapies with greater precision and impact.

“Sanofi and Medidata have worked together for a decade within clinical research, including a in 2024,” said Gaelan Ritter, global head of digital clinical development, Sanofi. “With this broadened relationship, we will continue harnessing the power of AI, optimizing our clinical trials, and ultimately expediting the delivery of groundbreaking medicines.”

Sanofi will employ Medidata’s expertise and capabilities in as part of this new enterprise agreement. Medidata will also provide strategic consulting and end-to-end operational support, empowering Sanofi to further streamline research processes.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process.”

To learn more about the Medidata Experiences, please visit .

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at . Listen to our latest podcast, , and follow us at @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Contact:

Medidata PR

Analyst Relations

Sanofi PR

Sandrine Guendoul |

Evan Berland |

Léo Le Bourhis |

Victor Rouault |

Timothy Gilbert |

Léa Ubaldi |

Attachment



EN
23/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

 PRESS RELEASE

Dassault Systèmes: Solid third quarter with strong operational perform...

Dassault Systèmes: Solid third quarter with strong operational performance: Confirming full-year EPS growth on adjusted revenue outlook Press Release VELIZY-VILLACOUBLAY, France — October 23, 2025 Dassault Systèmes: Solid third quarter with strong operational performance Confirming full-year EPS growth on adjusted revenue outlook (Euronext Paris: FR0014003TT8, DSY.PA) today reports its IFRS unaudited estimated financial results for the third quarter 2025 and nine months ended September 30, 2025. The Group’s Board of Directors approved these estimated results on October 22, 2025. This p...

 PRESS RELEASE

Dassault Systèmes : bon troisième trimestre avec une solide performanc...

Dassault Systèmes : bon troisième trimestre avec une solide performance opérationnelle ; Pour l’exercice 2025, hausse du BNPA confirmée et ajustement de la croissance du chiffre d’affaires Communiqué de Presse VELIZY-VILLACOUBLAY, France — 23 octobre 2025 Dassault Systèmes : bon troisième trimestre avec une solide performance opérationnelle ; Pour l’exercice 2025, hausse du BNPA confirmée et ajustement de la croissance du chiffre d’affaires (Euronext Paris : FR0014003TT8, DSY.PA) annonce aujourd’hui ses résultats financiers estimés non-audités en IFRS pour le troisième trimestre 2025 ...

 PRESS RELEASE

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedit...

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and today announced an expansion of their...

 PRESS RELEASE

Dassault Systèmes : Sanofi renforce son partenariat avec Medidata pour...

Dassault Systèmes : Sanofi renforce son partenariat avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Sanofi renforce son partenariat avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Une collaboration de plus de dix ans élargie autour des Medidata Experiences, permettant à Sanofi d’optimiser ses opérations, d’affiner la qualité de ses données et d’améliorer la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des solutions numériques...

 PRESS RELEASE

Dassault Systèmes: declaration of the number of outstanding shares and...

Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of September 30, 2025 Press ReleaseVELIZY-VILLACOUBLAY, France — October 7, 2025                 Declaration of the number of outstanding shares and voting rights as of September 30, 2025 (Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of September 30, 2025, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares: 1,341,653,585 Number of voting ri...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch